Last reviewed · How we verify

NexoBrid — Competitive Intelligence Brief

NexoBrid (NexoBrid) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzymatic debriding agent. Area: Wound Care / Burn Treatment.

marketed Enzymatic debriding agent Bromelain (serine protease) Wound Care / Burn Treatment Small molecule Live · refreshed every 30 min

Target snapshot

NexoBrid (NexoBrid) — MediWound Ltd. NexoBrid is a topical enzymatic debriding agent containing bromelain that selectively removes necrotic tissue from burn wounds.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NexoBrid TARGET NexoBrid MediWound Ltd marketed Enzymatic debriding agent Bromelain (serine protease)
EscharEx (EX-03) EscharEx (EX-03) MediWound Ltd phase 3 Enzymatic debriding agent Proteolytic enzymes (bromelain-derived)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzymatic debriding agent class)

  1. MediWound Ltd · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NexoBrid — Competitive Intelligence Brief. https://druglandscape.com/ci/nexobrid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: